Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5–17 Years With Angelman Syndrome (AS) With Deletion Genotype: NCT05630066, BP41315|2022–501844–14–00
Accessed August 29, 2024 at: